Literature DB >> 6273509

Characteristics of the cyclic AMP-phosphodiesterase activator in human brain tumours.

L Frattola, N Canal, S M Gaini, C Tonini, M Trabucchi.   

Abstract

The levels of the cyclic adenosine 3',5'-monophosphate (cyclic AMP)-phosphodiesterase (PDE) and the biochemical properties of its endogenous protein activator (PDEA) obtained from the human brain cortex and from different types of human cerebral tumours have been evaluated. The effects of the various PDEAs were studied measuring the activation of an activator-depleted cyclic AMP-PDE prepared from a normal brain cortex. The PDEA, obtained from normal and pathological tissues, did not change the affinity of the purified PDE for cyclic AMP, while it increased the Vmax of the enzyme. On the other hand, a cross-activation study showed that the PDEA lacked tissue specificity and was present in the tissue in excess over the enzyme. The levels of cyclic AMP-PDE and PDEA were much higher in normal than in tumoural tissues. The enzyme activity decreased in cerebral tumours more markedly than the protein activator. This biochemical pattern was more evident in the tumours of glial origin which are the most malignant.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6273509     DOI: 10.1016/0022-510x(81)90010-1

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  2 in total

1.  Evidence for a calmodulin inhibitory substance(s) isolated from human meningiomas.

Authors:  S D Antle; A K Ho; U P Kalyan-Raman
Journal:  J Neurooncol       Date:  1993-06       Impact factor: 4.130

2.  Calmodulin content in human central nervous system tumors.

Authors:  A J Bridges; A K Ho
Journal:  J Neurooncol       Date:  1989-07       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.